There are 2789 resources available
51P - Pooled analysis safety profile of futibatinib in patients with advanced solid tumors, including intrahepatic cholangiocarcinoma (iCCA)
Presenter: Funda Meric-Bernstam
Session: ePoster Display
52P - Assessment of futibatinib exposure–response (E–R) relationships in patients with advanced solid tumors, including cholangiocarcinoma (CCA)
Presenter: Antoine Hollebecque
Session: ePoster Display
53P - FGFR2 fusion and/or rearrangement profiling in Chinese patients with intrahepatic cholangiocarcinoma
Presenter: Xiao-Wu Huang
Session: ePoster Display
54P - Assessment of EU4 laboratory readiness for FGFR2 fusion testing of cholangiocarcinoma by NGS
Presenter: Marianna Sciortino
Session: ePoster Display
55P - Integrative genomic analysis identified primary cilium-associated genes by as novel key genes in biliary tract cancer (BTC)
Presenter: Massimiliano Salati
Session: ePoster Display
56P - Serum protein signatures as potential novel diagnostic biomarkers for biliary tract cancer
Presenter: Troels Christensen
Session: ePoster Display
57P - The characteristics of IDH mutations in Chinese bile duct carcinoma patients
Presenter: Yuwen Wang
Session: ePoster Display
58P - Intrahepatic cholangiocarcinoma (iCCA) hidden amongst the unknown: A retrospective analysis of cancer of unknown primary (CUP) cases from a tertiary cancer centre
Presenter: Alicia-Marie Conway
Session: ePoster Display
59TiP - Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)
Presenter: Jennifer Knox
Session: ePoster Display